Abstract |
The present study was undertaken to determine if (a) genistein induces topo II-mediated DNA damage in HT-29 colon cancer cells; and (b) if this damage is required to induce apoptosis. DNA damage was evaluated using the comet assay. Apoptosis was determined by the ethidium bromide/ acridine orange staining technique. DNA breakage was noted within 1 h of treatment. Apoptosis was only induced with high concentrations (>/=60 microM) of genistein. Marked inhibition of HT-29 cell growth was evident at concentrations ranging from 60 to 150 microM. This was associated with a cell cycle arrest at G(2)/M. Similar findings were obtained in SW-620 and SW-1116 colon cancer cell lines. Aclarubicin, a topo II antagonist, reduced genistein-induced DNA breaks but did not reduce apoptosis. These data suggest that, in colon cancer cells, topo II serves as the enzymatic target of genistein. Furthermore, topo II-mediated DNA cleavage is not required for the induction of apoptosis.
|
Authors | G I Salti, S Grewal, R R Mehta, T K Das Gupta, A W Boddie Jr, A I Constantinou |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 36
Issue 6
Pg. 796-802
(Apr 2000)
ISSN: 0959-8049 [Print] England |
PMID | 10762754
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antineoplastic Agents
- DNA, Neoplasm
- Growth Inhibitors
- Aclarubicin
- Genistein
- DNA Topoisomerases, Type II
|
Topics |
- Aclarubicin
(pharmacology)
- Antibiotics, Antineoplastic
(pharmacology)
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(genetics)
- Cell Cycle
(drug effects)
- Cell Division
(drug effects)
- Colonic Neoplasms
(genetics, pathology)
- DNA Damage
- DNA Topoisomerases, Type II
(drug effects, physiology)
- DNA, Neoplasm
(drug effects)
- Dose-Response Relationship, Drug
- Genistein
(pharmacology)
- Growth Inhibitors
(pharmacology)
- Humans
- Tumor Cells, Cultured
|